1-4 of 4
Caterina Nardella
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis

Andrea Lunardi, Shohreh Varmeh, Ming Chen, Riccardo Taulli, Jlenia Guarnerio, Ugo Ala, Nina Seitzer, Tomoki Ishikawa, Brett S. Carver, Robin M. Hobbs, Valentina Quarantotti, Christopher Ng, Alice H. Berger, Caterina Nardella, Laura Poliseno, Rodolfo Montironi, Mireia Castillo-Martin, Carlos Cordon-Cardo, Sabina Signoretti, Pier Paolo Pandolfi
Journal: Cancer Discovery
Cancer Discov (2015) 5 (5): 550–563.
https://doi.org/10.1158/2159-8290.CD-13-1050
Published: 03 May 2015
View article titled, Suppression of <em>CHK1</em> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis
Open the PDF for Suppression of <em>CHK1</em> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis in another window
Includes: Supplementary data
Journal Articles

Vulnerabilities of PTEN–TP53-Deficient Prostate Cancers to Compound PARP–PI3K Inhibition

Enrique González-Billalabeitia, Nina Seitzer, Su Jung Song, Min Sup Song, Akash Patnaik, Xue-Song Liu, Mirjam T. Epping, Antonella Papa, Robin M. Hobbs, Ming Chen, Andrea Lunardi, Christopher Ng, Kaitlyn A. Webster, Sabina Signoretti, Massimo Loda, John M. Asara, Caterina Nardella, John G. Clohessy, Lewis C. Cantley, Pier Paolo Pandolfi
Journal: Cancer Discovery
Cancer Discov (2014) 4 (8): 896–904.
https://doi.org/10.1158/2159-8290.CD-13-0230
Published: 03 August 2014
View article titled, Vulnerabilities of <em>PTEN</em>–<em>TP53</em>-Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
Open the PDF for Vulnerabilities of <em>PTEN</em>–<em>TP53</em>-Deficient Prostate Cancers to Compound PARP–PI3K Inhibition in another window
Includes: Supplementary data
Journal Articles

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf
Journal: Cancer Discovery
Cancer Discov (2012) 2 (11): 1048–1063.
https://doi.org/10.1158/2159-8290.CD-11-0336
Published: 11 November 2012
View article titled, Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Open the PDF for Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The APL Paradigm and the “Co-Clinical Trial” Project

Caterina Nardella, Andrea Lunardi, Akash Patnaik, Lewis C. Cantley, Pier Paolo Pandolfi
Journal: Cancer Discovery
Cancer Discov (2011) 1 (2): 108–116.
https://doi.org/10.1158/2159-8290.CD-11-0061
Published: 17 July 2011
View article titled, The APL Paradigm and the “Co-Clinical Trial” Project
Open the PDF for The APL Paradigm and the “Co-Clinical Trial” Project in another window